This publication expands on the series of posts published earlier on this blog. It reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market for biosimilars and the implications of these for potential savings.
Economists and regulatory experts from the US and Europe were invited to describe their research and offer their perspectives about what can be expected in the near- and medium-term. The publication includes updated insights that take account of changes since the seminar and add additional analyses of potential market impact.
Download Mattison, N., Mestre-Ferrandiz, J. and Towse, A. eds (2010) Biosimilars: How much entry and price competition will result? London: Office of Health Economics
Posted in Biosimilars, Pricing and Reimbursement | Tagged Monograph